ARCADIA BIOSCIENCES INC (RKDA) Fundamental Analysis & Valuation

NASDAQ:RKDA • US0390143032

Current stock price

1.32 USD
-0.02 (-1.49%)
Last:

This RKDA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RKDA Profitability Analysis

1.1 Basic Checks

  • In the past year RKDA has reported negative net income.
  • In the past year RKDA has reported a negative cash flow from operations.
  • RKDA had negative earnings in each of the past 5 years.
  • In the past 5 years RKDA always reported negative operating cash flow.
RKDA Yearly Net Income VS EBIT VS OCF VS FCFRKDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • With a Return On Assets value of -59.03%, RKDA is not doing good in the industry: 84.88% of the companies in the same industry are doing better.
  • RKDA's Return On Equity of -93.09% is on the low side compared to the rest of the industry. RKDA is outperformed by 74.42% of its industry peers.
Industry RankSector Rank
ROA -59.03%
ROE -93.09%
ROIC N/A
ROA(3y)-58.73%
ROA(5y)-43.88%
ROE(3y)-98.37%
ROE(5y)-71.81%
ROIC(3y)N/A
ROIC(5y)N/A
RKDA Yearly ROA, ROE, ROICRKDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • Looking at the Gross Margin, with a value of 37.81%, RKDA belongs to the top of the industry, outperforming 88.37% of the companies in the same industry.
  • In the last couple of years the Gross Margin of RKDA has grown nicely.
  • RKDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.63%
GM growth 5Y13.12%
RKDA Yearly Profit, Operating, Gross MarginsRKDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. RKDA Health Analysis

2.1 Basic Checks

  • RKDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • RKDA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for RKDA has been increased compared to 5 years ago.
  • RKDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RKDA Yearly Shares OutstandingRKDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
RKDA Yearly Total Debt VS Total AssetsRKDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -44.92, we must say that RKDA is in the distress zone and has some risk of bankruptcy.
  • RKDA's Altman-Z score of -44.92 is on the low side compared to the rest of the industry. RKDA is outperformed by 91.86% of its industry peers.
  • There is no outstanding debt for RKDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -44.92
ROIC/WACCN/A
WACC8.95%
RKDA Yearly LT Debt VS Equity VS FCFRKDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • RKDA has a Current Ratio of 3.67. This indicates that RKDA is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of RKDA (3.67) is better than 88.37% of its industry peers.
  • RKDA has a Quick Ratio of 3.03. This indicates that RKDA is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of RKDA (3.03) is better than 90.70% of its industry peers.
Industry RankSector Rank
Current Ratio 3.67
Quick Ratio 3.03
RKDA Yearly Current Assets VS Current LiabilitesRKDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. RKDA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 90.43% over the past year.
  • Looking at the last year, RKDA shows a small growth in Revenue. The Revenue has grown by 3.46% in the last year.
  • Measured over the past years, RKDA shows a very strong growth in Revenue. The Revenue has been growing by 33.95% on average per year.
EPS 1Y (TTM)90.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%152.54%
Revenue 1Y (TTM)3.46%
Revenue growth 3Y-9.38%
Revenue growth 5Y33.95%
Sales Q2Q%-15.29%

3.2 Future

  • Based on estimates for the next years, RKDA will show a very strong growth in Earnings Per Share. The EPS will grow by 23.39% on average per year.
  • The Revenue is expected to grow by 24.10% on average over the next years. This is a very strong growth
EPS Next Y49.49%
EPS Next 2Y23.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year20%
Revenue Next 2Y24.1%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RKDA Yearly Revenue VS EstimatesRKDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
RKDA Yearly EPS VS EstimatesRKDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1K -2K -3K

More info and screens

Find the best growth stocksShow best growing peers

1

4. RKDA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RKDA. In the last year negative earnings were reported.
  • Also next year RKDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RKDA Price Earnings VS Forward Price EarningsRKDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RKDA Per share dataRKDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RKDA's earnings are expected to grow with 23.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.39%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RKDA Dividend Analysis

5.1 Amount

  • RKDA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RKDA Fundamentals: All Metrics, Ratios and Statistics

ARCADIA BIOSCIENCES INC

NASDAQ:RKDA (4/10/2026, 8:00:01 PM)

1.32

-0.02 (-1.49%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)03-18
Earnings (Next)05-06
Inst Owners1.15%
Inst Owner Change0%
Ins Owners0.1%
Ins Owner Change0%
Market Cap4.49M
Revenue(TTM)5.17M
Net Income(TTM)-5.07M
Analysts82.86
Price Target12.24 (827.27%)
Short Float %0.7%
Short Ratio0.69
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)157.52%
Min EPS beat(2)102.48%
Max EPS beat(2)212.56%
EPS beat(4)3
Avg EPS beat(4)93.94%
Min EPS beat(4)-229.37%
Max EPS beat(4)290.08%
EPS beat(8)5
Avg EPS beat(8)38.49%
EPS beat(12)8
Avg EPS beat(12)30.28%
EPS beat(16)12
Avg EPS beat(16)30.8%
Revenue beat(2)0
Avg Revenue beat(2)-21.83%
Min Revenue beat(2)-32.82%
Max Revenue beat(2)-10.85%
Revenue beat(4)0
Avg Revenue beat(4)-13.45%
Min Revenue beat(4)-32.82%
Max Revenue beat(4)-0.65%
Revenue beat(8)3
Avg Revenue beat(8)-4.88%
Revenue beat(12)5
Avg Revenue beat(12)-8.99%
Revenue beat(16)6
Avg Revenue beat(16)-8.73%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.87
P/FCF N/A
P/OCF N/A
P/B 0.82
P/tB 0.83
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-2.47
Fwd EYN/A
FCF(TTM)-1.79
FCFYN/A
OCF(TTM)-1.79
OCFYN/A
SpS1.52
BVpS1.6
TBVpS1.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -59.03%
ROE -93.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.81%
FCFM N/A
ROA(3y)-58.73%
ROA(5y)-43.88%
ROE(3y)-98.37%
ROE(5y)-71.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.63%
GM growth 5Y13.12%
F-Score2
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.67
Quick Ratio 3.03
Altman-Z -44.92
F-Score2
WACC8.95%
ROIC/WACCN/A
Cap/Depr(3y)10.16%
Cap/Depr(5y)96.24%
Cap/Sales(3y)0.38%
Cap/Sales(5y)9.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%152.54%
EPS Next Y49.49%
EPS Next 2Y23.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.46%
Revenue growth 3Y-9.38%
Revenue growth 5Y33.95%
Sales Q2Q%-15.29%
Revenue Next Year20%
Revenue Next 2Y24.1%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y50.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.94%
OCF growth 3YN/A
OCF growth 5YN/A

ARCADIA BIOSCIENCES INC / RKDA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ARCADIA BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 4 / 10 to RKDA.


What is the valuation status for RKDA stock?

ChartMill assigns a valuation rating of 1 / 10 to ARCADIA BIOSCIENCES INC (RKDA). This can be considered as Overvalued.


What is the profitability of RKDA stock?

ARCADIA BIOSCIENCES INC (RKDA) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for RKDA stock?

The Earnings per Share (EPS) of ARCADIA BIOSCIENCES INC (RKDA) is expected to grow by 49.49% in the next year.